The IMID Forum
EULAR 2024 Review Podcast
Jun 19, 2024
Join Dr Sofia Ramiro, Prof. Rieke Alten & Assoc. Prof. Laura Coates as they discuss key sessions at EULAR 2024. Topics include baricitinib dosages for RA, effectiveness of different medications for RA & PsA, trials on spondyloarthritis medications, and safety of JAK inhibitors.
36:38
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Filgotinib at 100mg dose showed lower adverse events than 200mg, with stable safety profile over 4.3 years.
- Baricitinib at 4mg was more effective in achieving low disease activity and remission in RA patients compared to 2mg dosage.
Deep dives
Safety and Efficacy of Filgotinib in RA Treatment
The safety data of filgotinib in patients with moderate to severe active rheumatoid arthritis over 4.3 years revealed a stable safety profile with lower incidence of adverse events like hapestosta with the 100mg dosage compared to the 200mg dosage. Integrated safety analysis showed comparable results between dosage groups, with similar risks observed for all-cause mortality over 312 weeks.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
